Key facts
| Recalling firm | AbbVie Inc. |
|---|---|
| Manufacturer | Not disclosed in the FDA record. |
| Brand name | Not disclosed in the FDA record. |
| Product description | Refresh P.M., (Mineral Oil 42.5%, White Petrolatum 57.3%) Lubricant Eye Ointment, Net wt, 0.12 oz (3.5g) Tube, Distributed by: Allergen, an AbbVie company, Madison, NJ 07940, UPC code: 300230667043, |
| Classification | Class II |
| Recall number | D-0664-2024 |
| Report date | Not disclosed in the FDA record. |
| Status | Ongoing |
| Reason for recall | Lack of Assurance of Sterility: The impacted lots may contain a breach in the tube seal. |
What consumers should do
Facilities, clinicians, and consumers holding an affected unit or lot of Refresh P.M., (Mineral Oil 42.5%, White Petrolatum 57.3%) Lubricant Eye Ointment, Net wt, 0.12 oz (3.5g) Tube, Distributed by: Allergen, an AbbVie company, Madison, NJ 07940, UPC code: 300230667043, should stop using it for the purpose described in the recall notice and hold remaining stock pending instructions from AbbVie Inc.. FDA recall records typically direct the recalling firm to notify known accounts directly with a recall letter describing the specific corrective action -- replacement, field correction, refund, or return. Anyone who received the product through a distributor rather than directly from AbbVie Inc. should confirm with their supplier whether their specific lot or unit is on the affected list, since recall notices are lot- or unit-specific and not every unit of a product line is necessarily included. Questions about a specific unit's status should go to AbbVie Inc. directly or to the distributor that supplied it; Argus HQ is a public-record aggregator, not the recalling firm, and cannot confirm individual unit status.
What this classification means
A Class II recall is FDA’s middle classification. FDA assigns Class II when use of, or exposure to, the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. FDA still requires the recalling firm to notify affected accounts and submit status reports on the correction, though the monitoring intensity is lower than for a Class I recall. FDA's Center for Devices and Radiological Health (for devices) or Center for Drug Evaluation and Research (for drugs) reviews the classification and can require additional corrective action if the initial response is judged insufficient. Because this record is filed as Class II, professionals and consumers handling an affected lot should treat FDA's own classification -- not this page's summary of it -- as the authoritative risk signal. A Class I recall is FDA’s most serious classification. FDA assigns Class I when there is a reasonable probability that use of, or exposure to, the recalled product will cause serious adverse health consequences or death. This classification does not mean harm has already occurred in every case -- it reflects FDA’s assessment of the realistic worst-case risk profile of the defect described in the recall, based on the reason for recall reported by the firm. Class I recalls receive the closest FDA monitoring of the three classes: the recalling firm typically must submit a recall strategy, periodic status reports, and effectiveness checks confirming that the affected lots have actually been removed from distribution or corrected in the field.
AbbVie Inc.’s FDA history
Argus HQ has recorded 4 total FDA actions tied to AbbVie Inc.: 0 warning letters, 4 recalls, 0 approval records, and 0 Form 483 inspection citations.
Frequently asked questions
- Where can I verify this recall directly with FDA?
- The verbatim FDA record is the source of truth for every recall Argus HQ tracks — always confirm against fda.gov before acting.
- Is Refresh P.M., (Mineral Oil 42.5%, White Petrolatum 57.3%) Lu recalled?
- Yes. FDA lists a Class II recall by AbbVie Inc. for Refresh P.M., (Mineral Oil 42.5%, White Petrolatum 57.3%) Lubricant Eye Ointment, Net wt, 0.12 oz (3.5g) Tube, Distributed by: Allergen, an AbbVie company, Madison, NJ 07940, UPC code: 300230667043,, reported 20241002, with status "Ongoing." FDA recall number: D-0664-2024.
- What is the recall class for AbbVie Inc.'s recall?
- FDA classified this recall as Class II. A Class II recall is FDA’s middle classification. FDA assigns Class II when use of, or exposure to, the recalled product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
- Why was Refresh P.M., (Mineral Oil 42.5%, White Petrolatum 57.3%) Lu recalled?
- FDA's recall record states the reason as: Lack of Assurance of Sterility: The impacted lots may contain a breach in the tube seal.
Know if this happens again — we'll email you.
Free. No spam, just recall alerts for what you tell us to watch.
Related enforcement actions
Full FDA history for AbbVie Inc.Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2024). FDA Class II Recall: Refresh P.M., (Mineral Oil 42.5%, White Petrolatum 57.3%)… by AbbVie Inc. — Recall Details. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/recall/abbvie-d-0664-2024-2024-10-02
"FDA Class II Recall: Refresh P.M., (Mineral Oil 42.5%, White Petrolatum 57.3%)… by AbbVie Inc. — Recall Details." Argus HQ Research, Digital Empire Holdings LLC, 2024, argushq.ai/recall/abbvie-d-0664-2024-2024-10-02.
Argus HQ Research. "FDA Class II Recall: Refresh P.M., (Mineral Oil 42.5%, White Petrolatum 57.3%)… by AbbVie Inc. — Recall Details." Digital Empire Holdings LLC. Accessed August 27, 2026. https://argushq.ai/recall/abbvie-d-0664-2024-2024-10-02.
@misc{argushq_argushq_ai_recall_abbvie_d_0664_2024_2024_10_02_2024,
title = {FDA Class II Recall: Refresh P.M., (Mineral Oil 42.5%, White Petrolatum 57.3%)… by AbbVie Inc. — Recall Details},
author = {{Argus HQ Research}},
year = {2024},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/recall/abbvie-d-0664-2024-2024-10-02},
note = {Accessed: August 27, 2026}
}Source: FDA.gov — Recalls ↗

